''Yield curve to steepen in April due to expectations of improvement in the liquidity situation,'' says Sudhir Agrawal, Fund Manager, UTI MF. In an interview with Varsha Inamdar of Myiris.com, Sudhir Agrawal said, ''Investors should focus on the ... MyIris, 2 weeks ago
Idera Pharmaceuticals CEO Sudhir Agrawal After setbacks in cancer and respiratory disease, Idera Pharmaceuticals ($IDRA) has finally found some success with its toll-like receptor (TLR) program, touting encouraging results from a Phase II trial on ...FierceBiotech, 3 weeks ago Idera Pharmaceutical Up After Market; Big Moves in Agios and Idenix Bidness Etc, 1 week ago Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation Business Wire, 1 week ago Idera Pharmaceuticals announces positive data from Phase II psoriasis trial PredictWallStreet, 1 week ago
AHMEDABAD: The service tax commissioner on Thursday filed a complaint against Dr R M Agrawal of Chandramani Hospital in Shahibaug for hospitalizing an accused person by 'fabricating' medical papers to keep him out of Sabarmati jail. The complaint ...Times of India, 1 month ago
MUMBAI: The heightened volatility in the government bond market has prompted large entities to participate actively in the interest rate futures (IRFs) as they hedge their trading positions. Since April 7, the daily trading volumes on the NSE ...Economic Times, 3 days ago
Idera Pharmaceuticals, Inc., a biopharmaceutical company, has announced new preclinical data demonstrating the ability of its Toll-like receptor, or TLR, antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells ...Individual.com, 5 days ago IDERA PHARMACEUTICALS : Reports Preclinical Data at AACR 4 Traders, 1 week ago Idera Reports Preclinical Data at AACR Individual.com, 1 week ago
Name State Constituency Party Name Movable Assets (Rs) Immovable Assets (Rs) Total Assets (Rs) Nandan Nilekani Karnataka Bangalore South INC 76,65,95,17,41 44,34,39,808 77,10,29,57,219 Anil Kumar Sharma Bihar Jahanabad JD(U) ...New Indian Express, 1 week ago
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on..
/PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), ...ADVFN India, 2 weeks ago ORTHOFIX NV : Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera 4 Traders, 2 weeks ago
More from: , Nasdaq...and 2 other sources
It's been a wild week for Idera Pharmaceuticals (IDRA) . What started as a modest decline on March 19 after the stock bumped against its rising resistance level at about $6.85 a share turned into a blood bath on Monday when Summer Street Capital ...4 Traders, 3 weeks ago Idera Pharmaceuticals (IDRA) Climbs on Positive Top-line Data from IMO-8400 Phase 2 Trial HispanicBusiness.com, 3 weeks ago
Written by My Mobile Team 27 Mar 2014 at 5 hours ago The Indian telecom industry is one of the biggest in the world. Ensuring that the Indian consumer has their share of mobile connectivity and convenience are hundreds of thousands of people ...My Mobile, 3 weeks ago
NAGPUR: The Nagpur University's inefficient administration is infamous for its timidity. In the latest instance, NU has roped in senior counsel Avinash Gordey to plead the case on 250 banned colleges and removed Sudhir Puranik, who was pleading the ...Times of India, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!